Anti-Angiogenic Therapy in <i>ALK</i> Rearranged Non-Small Cell Lung Cancer (NSCLC)
The management of advanced lung cancer has been transformed with the identification of targetable oncogenic driver alterations. This includes anaplastic lymphoma kinase (<i>ALK</i>) gene rearrangements. ALK tyrosine kinase inhibitors (TKI) are established first-line treatment options in...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/16/8863 |